Quanterix Corp
QTRX6.010USD
+0.150+2.56%
Market hours （ET）Quotes delayed by 15 min
233.19MMarket Cap
LossP/E TTM
More Details of Quanterix Corp Company
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.
Company Info
Ticker SymbolQTRX
Company nameQuanterix Corp
IPO dateDec 07, 2017
CEODr. Masoud Toloue, Ph.D.
Number of employees471
Security typeOrdinary Share
Fiscal year-endDec 07
Address900 Middlesex Turnpike
CityBILLERICA
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code01821
Phone16173019400
Websitehttps://www.quanterix.com/
Ticker SymbolQTRX
IPO dateDec 07, 2017
CEODr. Masoud Toloue, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. David R. Walt, Ph.D.
Dr. David R. Walt, Ph.D.
Independent Director
Independent Director
1.86M
+0.12%
Dr. Masoud Toloue, Ph.D.
Dr. Masoud Toloue, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
278.40K
-0.44%
Mr. William P. (Bill) Donnelly
Mr. William P. (Bill) Donnelly
Independent Chairman of the Board
Independent Chairman of the Board
130.34K
+3.33%
Mr. Scott Mendel
Mr. Scott Mendel
Director
Director
28.65K
--
Dr. Myla P. Lai-Goldman, M.D.
Dr. Myla P. Lai-Goldman, M.D.
Director
Director
27.40K
--
Ms. Karen A. Flynn
Ms. Karen A. Flynn
Independent Director
Independent Director
26.41K
+20.04%
Mr. Jeffrey Thomas (Jeff) Elliott
Mr. Jeffrey Thomas (Jeff) Elliott
Independent Director
Independent Director
19.42K
+62.04%
Ms. Vandana Sriram, CPA
Ms. Vandana Sriram, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
9.28K
-2.41%
Dr. Ivana Magov Evi-liebisch, J.D., Ph.D.
Dr. Ivana Magov Evi-liebisch, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Paul M. Meister
Mr. Paul M. Meister
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. David R. Walt, Ph.D.
Dr. David R. Walt, Ph.D.
Independent Director
Independent Director
1.86M
+0.12%
Dr. Masoud Toloue, Ph.D.
Dr. Masoud Toloue, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
278.40K
-0.44%
Mr. William P. (Bill) Donnelly
Mr. William P. (Bill) Donnelly
Independent Chairman of the Board
Independent Chairman of the Board
130.34K
+3.33%
Mr. Scott Mendel
Mr. Scott Mendel
Director
Director
28.65K
--
Dr. Myla P. Lai-Goldman, M.D.
Dr. Myla P. Lai-Goldman, M.D.
Director
Director
27.40K
--
Ms. Karen A. Flynn
Ms. Karen A. Flynn
Independent Director
Independent Director
26.41K
+20.04%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q2
FY2024Q1
FY2023
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Product revenue
20.74M
68.51%
Service and other revenue
8.76M
28.95%
Collaboration and license revenue
771.00K
2.55%
By RegionUSD
Name
Revenue
Proportion
North America
19.38M
64.01%
EMEA
6.63M
21.92%
Asia Pacific
4.26M
14.07%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product revenue
20.74M
68.51%
Service and other revenue
8.76M
28.95%
Collaboration and license revenue
771.00K
2.55%
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Columbia Threadneedle Investments (UK)
6.49%
Portolan Capital Management, L.L.C.
6.41%
BlackRock Institutional Trust Company, N.A.
5.81%
The Vanguard Group, Inc.
5.47%
Kent Lake PR LLC
4.52%
Other
71.29%
Shareholders
Shareholders
Proportion
Columbia Threadneedle Investments (UK)
6.49%
Portolan Capital Management, L.L.C.
6.41%
BlackRock Institutional Trust Company, N.A.
5.81%
The Vanguard Group, Inc.
5.47%
Kent Lake PR LLC
4.52%
Other
71.29%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
30.87%
Investment Advisor
25.39%
Hedge Fund
12.76%
Individual Investor
6.60%
Research Firm
3.49%
Pension Fund
0.35%
Bank and Trust
0.21%
Family Office
0.13%
Venture Capital
0.05%
Other
20.15%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
391
37.62M
83.70%
-11.91M
2025Q1
401
40.45M
104.19%
-6.42M
2024Q4
388
38.02M
98.63%
-6.28M
2024Q3
386
36.47M
95.03%
-5.94M
2024Q2
394
35.66M
93.20%
-9.57M
2024Q1
395
35.56M
93.43%
-9.17M
2023Q4
388
34.77M
91.99%
-10.35M
2023Q3
382
36.53M
97.35%
-9.84M
2023Q2
388
36.74M
98.24%
-9.95M
2023Q1
389
37.25M
100.03%
-8.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Columbia Threadneedle Investments (UK)
3.00M
7.72%
+237.57K
+8.60%
Mar 31, 2025
Portolan Capital Management, L.L.C.
2.96M
7.63%
+375.57K
+14.51%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.68M
6.91%
-89.03K
-3.21%
Mar 31, 2025
The Vanguard Group, Inc.
2.53M
6.5%
+316.41K
+14.32%
Mar 31, 2025
Kent Lake PR LLC
2.92M
7.53%
+279.82K
+10.58%
Mar 31, 2025
Walt (David R)
1.86M
4.79%
+370.00K
+24.84%
Jun 13, 2025
William Blair Investment Management, LLC
1.11M
2.85%
+43.96K
+4.14%
Mar 31, 2025
UBS Financial Services, Inc.
1.11M
2.87%
+186.90K
+20.14%
Mar 31, 2025
Easterly Investment Partners LLC
1.33M
3.41%
+370.63K
+38.81%
Mar 31, 2025
Invenomic Capital Management LP
902.04K
2.32%
+546.67K
+153.83%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.58%
iShares Micro-Cap ETF
0.06%
Fidelity Enhanced Small Cap ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.58%
iShares Micro-Cap ETF
Proportion0.06%
Fidelity Enhanced Small Cap ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
